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Abnormalities of bone mineral metabolism and vascular
calcification are prevalent in patients with kidney failure.
Clinical management is based on biochemical targets, in
particular parathyroid hormone (PTH) concentrations, but
this has many limitations including high biological variation.
A possible alternative is bone-specific alkaline phosphatase
(ALP); therefore, we evaluated the biological variation of this
marker in patients undergoing hemodialysis. Bone ALP was
measured in non-fasting serum samples taken twice a week
over a 6-week period in 22 stable hemodialysis patients and
12 healthy volunteers. The within-individual coefficients of
variance were calculated and used to derive the critical
difference required to be certain that an observed change
was significant. The coefficient of variance for bone ALP was
significantly higher in hemodialysis patients compared to
healthy individuals. Seven samples were required to estimate
the homeostatic set point of bone ALP, within 10%, in a
hemodialysis patient. The concentration of serial bone ALP
measurements would need to change by 36% between any
two measurements before it can be considered a significant
change. Since the biological variation of bone ALP is less than
half that reported for PTH, our study provides further support
for the use of bone ALP as an alternative marker of bone
mineral metabolism in the setting of chronic kidney
disease–mineral and bone disorder.
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Patients with kidney failure frequently develop chronic
kidney disease–mineral and bone disorder (CKD-MBD).1
This term encompasses biochemical abnormalities such
as secondary hyperparathyroidism along with alterations in
bone morphology and extraskeletal (vascular) calcification.1
Studies have repeatedly demonstrated that CKD-MBD
contributes to morbidity2 and mortality1,3 in the CKD popu-
lation. The gold standard for diagnosis of the bone compo-
nent of CKD-MBD is bone histomorphometry. However,
this is a costly, painful, and invasive procedure that is
not routinely performed in clinical practice. Instead, clinical
management focuses on biochemical targets,4,5 especially
plasma parathyroid hormone (PTH). The limitations of PTH
as a marker in this respect are increasingly appreciated.6
Recently, we have demonstrated the high biological vari-
ability of PTH in patients on hemodialysis.7 Our data showed
that in hemodialysis patients at least 26 specimens are
required in order to estimate an individual’s homeostatic
set point within 10%. In addition, the concentration of
PTH must differ by 472% between any two measurements
before it can be considered a significant change. These data
raise further concerns over the use of PTH and PTH target
concentrations in CKD-MBD and emphasize the need for
better markers.
A possible alternative is serum bone–specific alkaline
phosphatase (bone ALP), a marker of bone turnover.
However, no data concerning the biological variation
of bone ALP in the hemodialysis population have been
reported. The measurement of any laboratory analyte is
subject to error or variation, which can be divided into three
categories: preanalytical, analytical, and biological. If sources
of preanalytical variation are minimized, then intraindividual
biological variation (CVI) can be estimated by removing
the contribution of analytical variation (CVA) from total
variation (CVT).
8 These numerical data can be used to
evaluate the number of samples required to estimate an
individual’s homeostatic set point and calculate the critical
difference, also known as the reference change value. This is
the degree of change that must be observed in any measured
substance before that change can be considered statistically
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significant, and therefore has obvious clinical importance
in the monitoring of any patients with a chronic condition.
The importance of understanding biological variation in
nephrology is increasingly realized.9 The aims of this study
were to establish: (i) the within-subject biological variation of
bone ALP in hemodialysis patients, (ii) how many measure-
ments are required to estimate a true homeostatic set point in
any individual, (iii) the critical difference, and (iv) how these
results compare with those we previously reported for PTH.
RESULTS
Clinical details of our study group have been reported
previously but are reproduced in Table 1 for ease of reference.
Among the hemodialysis patients, no changes were observed
in weight, Kt/V, energy, and protein and mineral intakes
at the beginning and end of the study (P40.05). Median
(range) serum total ALP activity in all of the samples
included in the study was 76 (30–289) U/l, compared with
76 (30–288) U/l in our original report,7 confirming that there
had been no loss of total ALP activity during frozen storage.
Cochran’s test for outliers among duplicates identified two
bone ALP measurements, both from the hemodialysis group
(sample 5 from subject 9 and sample 11 from subject 19);
these samples were excluded from statistical analysis.
The CVs of these duplicates were the only ones above 10%.
Cochran’s test identified two samples that needed to be
excluded from within-subject variance estimations (sample
6 from subject 7 and sample 3 from subject 25). Reed’s test
did not identify any outliers. Sample 11 from subject 13 and
sample 2 from subject 26 were excluded because of suspected
contamination (undetectable total ALP result). A number of
individuals’ observations displayed a significant trend over
the length of the investigation (e.g., a consistent rise or
fall in analyte concentration over time; Supplementary
Table S1 and Figure S1 online). Analysis of variance
performed both including and excluding the subjects
showing trends yielded essentially the same estimates of
CVA and CVI (Supplementary Table S2 online): consequently,
the data presented in this paper include all subjects (i.e.,
those who both did and did not show trends in concentration
over time).
Figure 1 shows the individual median and range
concentrations for bone ALP in all the study subjects. The
CVI for bone ALP was significantly higher for the hemo-
dialysis patients compared with the healthy volunteers
(Po0.05), resulting in a greater number of specimens being
required to estimate an individual’s homeostatic set point
and a higher critical difference (Table 2). No significant
difference (P40.05) in the CVI for bone ALP was observed
between those patients who underwent dialysis in the
morning (12.9%) and those who underwent dialysis in the
afternoon (12.2%).
Bone ALP concentrations were correlated with total ALP
activity irrespective of whether all subjects were considered
together (rs 0.86) or whether the healthy control group
(rs 0.94) and hemodialysis patients (rs 0.86) were considered
separately (Po0.0001 in all three cases). There were no
significant correlations (P40.05) between either bone ALP
or total ALP and PTH irrespective of whether controls and
patients were considered separately or together.
DISCUSSION
Bone ALP is an 80-kDa glycoprotein found on the surface
of osteoblasts. Its concentration generally reflects the rate
of bone formation in skeletal tissue. As bone formation is
coupled to bone resorption, bone ALP measurements provide
an indication of overall bone metabolism. Bone ALP
can be used as a marker of bone turnover in CKD-MBD
patients.10,11 In this study, we have described for the first
time the biological variation of bone ALP in hemodiaylsis
Table 1 | Characteristics of study subjects
Healthy volunteers Hemodialysis patients
n 12 22
Age, yearsa 38.5 (13.3), 24–61 67.7 (12.3), 42–90b
Female, n (%) 8 (67%) 11 (50%)
Weight, kga NA 78.2 (16.5), 53.5–113.0
Dialysis adequacy (Kt/V)a NA 1.42 (0.31)
Daily energy intake (kcal/kg)a NA 21.4 (7.9), 10.0–38.0
Daily protein intake (g/kg)a NA 0.80, 0.30–1.30
Daily phosphate intake (mg)a NA 982 (259), 524–1482
Daily calcium intake (mg)a NA 723 (201), 337–1186
Cause of renal failure, n NA Small kidneys/unknown etiology (7), glomerulonephritis (4),
membranous nephropathy (3), pyelonephritis (2), diabetes mellitus (2),
renal vascular disease (2), IgA nephropathy (1),
Wegener’s granulomatosis (1)
Bone ALP concentration (mg/l)a 13.3, 4.8–26.8 15.2, 7.8–85.0
Total ALP activity (U/l)a 56, 32–105 79, 43–275b
PTH concentration (ng/l)a 43, 22–101 168, 18–978b
Abbreviations: ALP, alkaline phosphatase; IgA, immunoglobulin A; NA, not applicable; PTH, parathyroid hormone.
aData obtained at the beginning of study.
bSignificantly (Po0.05) different from the value in the healthy controls.
Values for continuous variables are expressed as mean (s.d.), range (where given), or median, range. Further details may be found in Gardham et al.7
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patients and compared it against that we previously described
for PTH.7
The CVI for bone ALP that we observed among
healthy subjects (7.7%) is similar to that reported by others
(3.4 (ref. 12), 6.6 (ref. 13), 7.7 (ref. 14), 9.0% (ref. 15)).
Differences between reports could, for example, reflect other
studies that only included exclusively premenopausal12 or
postmenopausal15 women.
Biological variation for bone ALP was higher among
hemodialysis patients than healthy volunteers, as we pre-
viously observed for total ALP, calcium, phosphate, and
PTH.7 We cannot exclude the possibility that this reflects the
older age of our hemodialysis patients compared with the
healthy volunteers. However, CKD-MBD is almost universal
among patients with kidney failure, and it is perhaps not
unexpected that these markers will show a significantly
higher CVI in hemodialysis patients. Similar observations
have been made for total ALP when comparing healthy
controls (CVI 4.5%) with Pagetic patients (CVI 12.4%).
12
The higher CVI in disease compared with health clearly
affects the critical difference and number of specimens
required to estimate an individual’s homeostatic set point.
As noted by others,16 variance components derived from
healthy subjects cannot necessarily be extrapolated to
pathological situations.
However, the CVI of bone ALP in hemodialysis patients
(12.5%) was less than half of that previously described for
PTH (25.6%), resulting in a lower number of specimens
required to estimate an individual’s homeostatic set point
(7 vs. 26) and a lower critical difference (36% compared with
72%; Table 2). In addition, the biological variation of bone
ALP in dialysis patients appeared to be consistent throughout
the day, whereas we previously found suggestive evidence
that the CVI of PTH differed between the morning and
afternoon.7
The lower biological variation of bone ALP compared
with PTH represents a potentially important advantage of
this marker in the monitoring and treatment of CKD-MBD.
More reliance can thus be placed on results and on changes
in concentration. In addition to higher biological variation,
PTH is an imperfect marker of CKD-MBD for a variety of
other reasons including the following: analyte instability;17
significant phlebotomy sample site variation;18 standardiza-
tion-related assay variability;19 nonspecificity of assays, with
which B50% of measured PTH is of a biologically inactive
form;20 racial variation in the PTH–histology relationship;21
a strong relationship between PTH and body mass index22
and nutritional/inflammatory status;23 poor histological
correlation to target ranges;24 and skeletal resistance.25
Furthermore, attainment of the recommended PTH target
range has not been shown to improve the risk of death or
cardiovascular events within the CKD population.26,27 These
issues raise significant concerns over the validity of specific
target concentrations of PTH and the use of PTH in
monitoring response to treatment.
There are many potential biomarkers of skeletal health and
integrity, some of which are difficult to use and to interpret
in kidney failure on account of renal function affecting their
plasma concentrations. One of the best known, and best
established, of these is the plasma activity of ALP, which is
increased in osteitis fibrosa.28 High plasma ALP activity
among hemodialysis patients is associated with increased
risks of all-cause and cardiovascular mortality,29–31 and it has
been shown to be more sensitive to the effects of vitamin D
replacement than PTH.32,33 However, the use of total ALP
in this context has always been considered limited by its
nonspecificity for bone disease, with only B50% of blood
activity being attributable to bone ALP.
Specific immunoassays for bone ALP have been available
for nearly 20 years, but their use has not become widespread
in nephrology, probably reflecting perceived difficulties of
measurement and the primary role assigned to PTH in the
management of CKD-MBD. Bone ALP has a relatively long
half-life of 1–2 days, and its plasma concentration depends
only on its rate of release from the osteoblasts and on its
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Figure 1 |A box plot showing median (horizontal line),
upper, and lower quartile (large rectangle), as well as range
(represented by the whiskers), for serum bone alkaline
phosphatase (bALP) concentration for hemodialysis (HD)
patients (subjects 1–22) and the healthy volunteers (subjects
23–34). The dashed lines represent the upper reference limit
(22.4mg/l) for the assay used. Note that study numbers are the
same as in our previously published study,7 enabling direct
comparison with parathyroid hormone (PTH) variability and
concentrations within subjects.
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hepatic degradation. Unlike PTH, bone ALP does not
accumulate with progressive loss of GFR.34 Further, bone
ALP has a good relationship with bone histology10,11,21 and
bone mineral density35 and is also a good predictor, with
DEXA-derived bone mineral density, of future fracture risk in
dialysis patients.36 In addition, high concentrations of bone
ALP are associated with increased cardiovascular and all-
cause mortality in kidney failure patients.37 Mechanistically,
there is evidence implicating bone ALP as a proponent of
vascular calcification in CKD-MBD.38–40 This is supported
by data showing a significant association between serum ALP
activity and coronary artery calcification in hemodialysis
patients, with serum ALP 4120 U/l being a robust predictor
of calcification.41 Hence, our data, together with other
published literature, advocate the use of bone ALP as a
potential alternative marker of CKD-MBD, providing a living
biopsy of bone activity with additional potential value in the
risk stratification of hemodialysis patients.
Our samples were stored for 2 years at 801C before
analysis. However, no loss in serum total ALP activity was
seen during this time. As bone ALP represents a significant
component of total ALP, it is a reasonable assumption
that bone ALP was also stable under these storage conditions.
The CVI, and consequently the critical difference, for total
ALP was lower than that for bone ALP; there was a strong
correlation between bone ALP and total ALP; as noted above,
total ALP has strong relationships with outcome in patients
with kidney failure; further, total ALP is easier and cheaper to
measure in laboratories than bone ALP. It is possible that the
value of total ALP as a marker of CKD-MBD should be
reassessed. However, we feel that its nonspecificity for bone
tissue will always remain an impediment to clinical
acceptance in this situation. Further, bone ALP shows
stronger relationships with histological changes than total
ALP, and better sensitivity and specificity for both low- and
high-turnover bone disease.10 Although bone ALP requires
far fewer samples than PTH to establish a patient’s homeo-
static set point, it is still clear that a single measurement is
insufficient.
The significance of the reduced critical difference for bone
ALP compared with PTH is best appreciated by application
to a clinical example. In the study of Fletcher et al.11, who
used the forerunner of our assay, mean bone ALP concen-
trations of 44 mg/l were observed in dialysis patients with
severe hyperparathyroidism (mean PTH 780 ng/l) compared
with 10 mg/l among patients with adynamic bone disease
(mean PTH 140 ng/l). Applying critical differences (Table 2)
to the values lying exactly intermediate between these two
groups (bone ALP 27 mg/l and PTH 460 ng/l), it can be seen
that a 72% increase in PTH (just significant) will result in a
concentration of 790 ng/l, in excess of the mean of the group
with severe hyperparathyroidism, whereas a 72% decrease
would result in a concentration below the mean of the group
with adynamic bone disease (129 ng/l). This, in part, may
explain the poor histological correlation of bone biopsy
specimens to PTH target ranges.24 For bone ALP, the same
manipulation would result in concentrations of 17 mg/l and
37 mg/l, above and below the adynamic and severely hyper-
parathyroid means, respectively. This illustrates how the
better signal-to-noise ratio of bone ALP compared with PTH
would enable clinicians to better interpret changes in
concentrations in their patients.
The concentrations of bone ALP we observed in our
hemodialysis patients (mean 20 mg/l) were only moderately
elevated compared with the control group. Urena et al.10
observed mean bone ALP concentration of 64 mg/l among
patients with osteitis fibrosa, and Fletcher et al.11 observed
mean bone ALP concentrations of 44 mg/l in dialysis patients
with severe hyperparathyroidism (mean PTH 780 ng/l). Two
of our patients (subjects 17 and 19) had markedly increased,
and one (subject 4) marginally increased, median bone ALP
concentrations: these subjects also had high PTH concen-
trations (4400 ng/l). Bone ALP concentrations were not
significantly increased in the remaining patients. Overall,
this would be consistent with an interpretation that the
CKD-MBD among our cohort was at the milder end of the
spectrum, possibly reflecting a shift in the phenotype of
CKD-MBD away from high-turnover bone disease, as noted
by others,42 compared with these earlier studies. However,
the majority of the patients had PTH concentrations in excess
of the upper limit of normal. In the absence of bone biopsy
data, one cannot draw strong conclusions in this regard, but
Table 2 | Estimation of variance components for healthy volunteers and hemodialysis patients including the critical difference
and the number of specimens required to estimate the homeostatic set point of an individual (within ±10,±20, and±30%
with a confidence of 95%)
Healthy volunteers Hemodialysis patients
Bone ALP Total ALPa PTHa Bone ALP Total ALPa PTHa
CVA 3.0 1.2 3.5 3.4 0.9 3.6
CVI 7.7 5.8 19.2 12.5
b 9.9b 25.6b
No. of specimens ±10% 3 1 15 7 4 26
No. of specimens ±20% 1 1 4 2 1 6
No. of specimens ±30% 1 1 2 1 1 3
Critical difference (%) 23 16 54 36 27 72
Abbreviations: ALP, alkaline phosphatase; CVA , analytical variance; CVI, intraindividual variance; PTH, parathyroid hormone.
aPTH and ALP data are same as published previously7 and are shown here for comparison.
bSignificantly different than the equivalent variance component in the healthy volunteers (Po0.05).
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it is tempting to speculate that the high PTH concentrations
may not be reflecting increased bone turnover in all of these
individuals, because of some of the problems alluded to
above. As we have noted previously,7 our cohort is fairly
typical of hemodialysis cohorts in the UK at the present time,
and we therefore feel our conclusions are generally applicable
to this population.
In conclusion, we propose that the relatively low bio-
logical variability of bone ALP provides further suggestive
evidence that it could be a better alternative to PTH
measurement in the management of CKD-MBD in the
adult hemodialysis population. Whichever marker is used, it
is clear that clinicians cannot rely on single measurements
assessed against rigid and somewhat arbitrary management
targets, but instead must look serially for trends in patient
results.
MATERIALS AND METHODS
Twenty-two patients receiving three-times-weekly hemodialysis for
renal failure at the Kent Kidney Care Centre were recruited in 2008,
with their informed consent. Ethical approval for this study was
granted from the East Kent Research Ethics Committee (reference
number 08/H1103/45). Complete details of the patients included in
the study and of the exclusion criteria applied have been published
previously.7 Briefly, all patients had been on hemodialysis for a
minimum of 3 months, and their pharmacologic prescription and
dietary intake remained consistent throughout the study period.
Most were receiving 1a-hydroxycholecalciferol (Alfacalcidol) and
calcium carbonate (Calcichew). To standardize preanalytical vari-
ables, only patients who underwent dialysis on Monday, Wednesday,
and Friday were recruited. Twelve volunteer staff members who had
a negative proteinuria screening test (Multistix 10 SG, Siemens
Healthcare, Surrey, UK) and estimated GFR X60 ml/min per
1.73 m2 (ref. 43) also participated in this study.
Non-fasting blood samples were collected before dialysis from the
vascular access (arteriovenous fistula) of the patients before their
dialysis sessions on Wednesday and Friday for 6 weeks (i.e., 12
samples per patient). Blood was collected from patients who
underwent dialysis in the morning (n¼ 13) between 0800 and 1000
hours, and from patients who underwent dialysis in the afternoon
(n¼ 9) between 1300 and 1500 hours. Concurrently, samples were
collected from the 12 healthy volunteers on Wednesday and Friday
(between 0930 and 1130 hours). Blood was collected in serum
separator tubes (Becton-Dickinson Vacutainer Systems, Oxford, UK),
and serum was separated within 4 h of venepuncture and stored at
801C for 22 months until assayed. Before analysis, samples were
thawed at room temperature for 48 h to enable reactivation of ALPs
and then mixed by inversion. For analyte measurement, each sample
was measured in duplicate in random order. A single operator
performed all analyses using a single instrument.
Serum total ALP was measured on an Abbott Architect c8000
automated system (Abbott Laboratories, Abbott Park, IL) at 371C
using essentially the method described by the International Federation
of Clinical Chemistry.44 The adult reference range for this assay is
42–128 U/l.45 Serum concentrations of bone ALP were determined
using a solid-phase, monoclonal antibody immunoenzymetric assay
(Ostases BAP, Immunodiagnostic Systems, Tyne & Wear, UK). The
upper limit of the reference range for this assay is 22.4 mg/l
(manufacturer’s product information).
Data analyses
All calculations and statistical analyses were carried out with Minitab
(Coventry, UK) and Analyse-ItTM (Analyse-It Software, Leeds, UK).
Comparisons between dietary intakes, weight, and Kt/V at the start
and end of the study were made using paired t-test or Wilcoxon
match-pairs signed ranks test as appropriate. Comparisons between
total ALP, bone ALP, and PTH concentrations at the start of the
study between healthy controls and patients were made using the
Mann–Whitney U-test. Cochran’s criterion test was used to identify
outliers among duplicate measurements and among within-subject
variances, and the Reed test to eliminate mean outlying values.8 We
tested individuals’ data for normality using the Shapiro–Wilk test:
approximately one-third of the data sets were not normally
distributed. All variance estimates were therefore derived using
natural logarithmic–transformed data after exclusion of outliers as
recommended,8 and then back-transforming the data. Analytical
(SDA
2) and intraindividual variances (SDI
2) were calculated by nested
analysis of variance according to the methods of Fraser and Harris.8
Coefficients of variation (CVA and CVI) were calculated as
CV%¼ SD/mean analyte concentration  100. The F-test was used
to compare: (i) CVI obtained for the healthy volunteers and the
hemodialysis patients and (ii) CVI among patients who underwent
dialysis in the morning with those who underwent dialysis in the
afternoon. A P-value of o0.05 was set for statistical significance.
As the aim of the study was to establish biological variation under
steady-state conditions, exploratory analysis was conducted using
linear regression analysis in order to discover whether the natural
logarithmic data for bone ALP concentrations followed a trend over
the 6-week period (e.g., a consistent rise or fall in concentrations).
Analysis of variance analysis to determine CVI was then performed
both including and excluding the subjects showing trends. Subjects
with T values greater than þ 2 or less than 2 had measurements
that showed a significant trend. The critical difference, which is the
difference that must be exceeded between two sequential results
for a significant change to have occurred in either direction at
Po0.05, was derived by applying the standard equation
[2.77 (SDA2 þ SDI2)1/2]. The number of specimens required to
estimate the homeostatic set point of an individual to within ±10%
with 95% confidence was also calculated, and this analysis was
adjusted to consider ±20 and ±30% limits. Spearman’s correlation
was used to assess relationships between bone ALP and both total ALP
and PTH: in all cases the mean value for each subject was used.
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Figure S1. Serum bone alkaline phosphatase (bALP) concentration
over the six-week period for (A) hemodialysis patients (subjects 1-22)
and (B) healthy volunteers (subjects 23–34).
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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